Blueprint Medicines Q4 EPS $(1.53) Beats $(1.62) Estimate, Sales $34.11M Beat $29.24M Estimate
Blueprint Medicines Q4 EPS $(1.53) Beats $(1.62) Estimate, Sales $34.11M Beat $29.24M Estimate
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.62) by 5.56 percent. This is a 13.33 percent decrease over losses of $(1.35) per share from the same period last year. The company reported quarterly sales of $34.11 million which beat the analyst consensus estimate of $29.24 million by 16.65 percent. This is a 33.82 percent decrease over sales of $51.53 million the same period last year.
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(1.62) by 5.56 percent. This is a 13.33 percent decrease over losses of $(1.35) per share from the same period last year. The company reported quarterly sales of $34.11 million which beat the analyst consensus estimate of $29.24 million by 16.65 percent. This is a 33.82 percent decrease over sales of $51.53 million the same period last year.
Blueprint Medicines(納斯達克:BPMC)公佈季度虧損為每股1.53美元,比分析師普遍預期的1.62美元高出5.56%。這比去年同期每股虧損1.35美元減少了13.33%。該公司公佈季度銷售額為3411萬美元,比分析師普遍預期的2924萬美元高出16.65%。這比去年同期5153萬美元的銷售額下降了33.82%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧